Harpoon Therapeutics Announces Acceptance of Five Abstracts
Preclinical abstracts for investigational T cell engagers, HPN328 and HPN217, in mouse models provide further validation of Harpoon’s proprietary......
Kinnate Biopharma Inc. to Report First Clinical Data for
Company has initiated enrollment of patients into the monotherapy expansion cohorts Company to host a virtual investor webcast on April 17, 2023, to......
CRISPR Therapeutics to Present at the American Association
ZUG, Switzerland and BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating......
Kura Oncology Announces Acceptance of Two Abstracts for
– Presentations to highlight preclinical data supporting combination of FTIs with KRASG12C inhibitors and tyrosine kinase inhibitors – SAN DIEGO, March ......
Ascendant Resources Strengthens Executive Team
Mr. Michael McAllister appointed Vice President, Investor Relations Mr. Chris MacInnis appointed Director, Geology and Resources TORONTO, March 14, 2023......
Nurix Therapeutics Announces Presentations at the American
Nurix to report additional preclinical data for its targeted BTK degraders NX-2127 and NX-5948......
Sana Biotechnology Announces the Acceptance of Four
Late-breaking poster presentation to highlight preclinical data demonstrating that the increased potency of CD8-targeted fusosomes enhances CAR gene......
Cullinan Oncology to Present New Preclinical Data for
CLN-619 is a MICA/B directed humanized IgG1 antibody being studied in a global Phase 1 clinical trial in patients with advanced solid tumors. Initial......